Rituximab biosimilar - Center of Molecular Immunology

Drug Profile

Rituximab biosimilar - Center of Molecular Immunology

Alternative Names: Monoclonal anti CD20 chimeric antibody - CIMAB; RituxCIM

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; CIMAB
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 14 Jan 2016 Phase-I/II clinical trials in Rheumatoid arthritis in Cuba (IV) (CIMAB SA pipeline; January 2016)
  • 15 Jul 2013 Biomarkers information updated
  • 18 Oct 2011 Phase-I/II clinical trials in B-cell lymphoma (second-line therapy or greater) in Cuba (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top